| Thomas E Schryver, MD | |
|
4230 Hamilton Blvd, Sioux City, IA 51104-1137 | |
| (712) 239-4300 | |
| (712) 239-2866 |
| Full Name | Thomas E Schryver |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 4230 Hamilton Blvd, Sioux City, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134194558 | NPI | - | NPPES |
| 8064378 | Medicaid | IA | |
| 7765572 | Medicaid | SD | |
| 75305796312 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 28275 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Recover Health | Sioux city, IA | Home health agency |
| Hospice Of Siouxland | Sioux city, IA | Hospice |
| St Lukes Regional Medical Center | Sioux city, IA | Hospital |
| Mercyone Siouxland | Sioux city, IA | Hospital |
| Hawarden Regional Healthcare | Hawarden, IA | Hospital |
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Family Health Care Of Siouxland Plc | 7315839412 | 51 |
| Hawarden Regional Healthcare | 0547257990 | 11 |
News Archive
Researchers at the Hebrew University of Jerusalem have achieved, for the first time, the generation of neuronal cells from stem cells of Fragile X patients. The discovery paves the way for research that will examine restoration of normal gene expression in Fragile X patients.
The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
The global obesity epidemic has been escalating for decades, yet long-term prevention efforts have barely begun and are inadequate, according to a new paper from international public health experts published in the August 25, 2011 edition of the journal The Lancet.
› Verified 9 days ago
| Entity Name | Family Health Care Of Siouxland Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437170685 PECOS PAC ID: 7315839412 Enrollment ID: O20040325000519 |
News Archive
Researchers at the Hebrew University of Jerusalem have achieved, for the first time, the generation of neuronal cells from stem cells of Fragile X patients. The discovery paves the way for research that will examine restoration of normal gene expression in Fragile X patients.
The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
The global obesity epidemic has been escalating for decades, yet long-term prevention efforts have barely begun and are inadequate, according to a new paper from international public health experts published in the August 25, 2011 edition of the journal The Lancet.
› Verified 9 days ago
| Entity Name | Hawarden Regional Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841261104 PECOS PAC ID: 0547257990 Enrollment ID: O20040428000001 |
News Archive
Researchers at the Hebrew University of Jerusalem have achieved, for the first time, the generation of neuronal cells from stem cells of Fragile X patients. The discovery paves the way for research that will examine restoration of normal gene expression in Fragile X patients.
The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
The global obesity epidemic has been escalating for decades, yet long-term prevention efforts have barely begun and are inadequate, according to a new paper from international public health experts published in the August 25, 2011 edition of the journal The Lancet.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas E Schryver, MD 814 Pierce Street, Suite 102, Sioux City, IA 51101-1058 Ph: (712) 226-2600 | Thomas E Schryver, MD 4230 Hamilton Blvd, Sioux City, IA 51104-1137 Ph: (712) 239-4300 |
News Archive
Researchers at the Hebrew University of Jerusalem have achieved, for the first time, the generation of neuronal cells from stem cells of Fragile X patients. The discovery paves the way for research that will examine restoration of normal gene expression in Fragile X patients.
The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
The global obesity epidemic has been escalating for decades, yet long-term prevention efforts have barely begun and are inadequate, according to a new paper from international public health experts published in the August 25, 2011 edition of the journal The Lancet.
› Verified 9 days ago
Richard J. Kipp, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3520 Singing Hills Blvd, Sioux City, IA 51106 Phone: 712-294-7400 Fax: 712-294-7436 | |
Dylan C Greene, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1021 Nebraska St, Sioux City, IA 51105 Phone: 712-252-2477 Fax: 712-252-5920 | |
Kornelia Kellogg, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2501 Pierce St, Sioux City, IA 51104 Phone: 712-294-5000 Fax: 712-294-5092 | |
Michael John Jung, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2501 Pierce St, Sioux City, IA 51104 Phone: 712-294-5000 Fax: 712-294-5091 | |
Daniel Irwin, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2501 Pierce St, Sioux City, IA 51104 Phone: 712-294-5000 Fax: 712-294-5091 | |
Rodney L. Cassens, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3500 Singing Hills Blvd, Ste 100, Sioux City, IA 51106 Phone: 712-274-4250 Fax: 712-274-4260 | |
Eric Ryan Monk, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Stone Park Blvd, Sioux City, IA 51104 Phone: 712-279-3290 |